Nurses must have the most up-to-date information possible to provide accurate patient education and competent nursing care with prostate cancer. This book addresses those issues in a concise and thorough manner. Chapters on risk factors and different treatment modalities used in cancer management are included.

With cancer-related deaths projected to rise to 10.3 million people by 2020, the need to prevent, diagnose, and cure cancer is greater than ever. Cancer Imaging presents readers with the most up-to-date imaging instrumentation, general and diagnostic applications for various cancers, with an emphasis on lung and breast carcinomas--the two major worldwide malignancy types. This book discusses the various imaging techniques used to locate and diagnose tumors, including ultrasound, X-ray, color Doppler sonography, PET, CT, PET/CT, MRI, SPECT, diffusion tensor imaging, dynamic infrared imaging, and magnetic resonance spectroscopy. It also details strategies for imaging cancer, emphasizing the importance of the use of this technology for clinical diagnosis. Imaging techniques that predict the malignant potential of cancers, response to chemotherapy and other treatments, recurrence, and prognosis are also detailed. - Concentrates on the application of imaging technology to the diagnosis and prognosis of lung and breast carcinomas, the two major worldwide malignancies - Addresses the relationship between radiation dose and image quality - Discusses the role of molecular imaging in identifying changes for the emergence and progression of cancer at the cellular and/or molecular levels

Rising health care costs are a central fiscal challenge confronting the United States. National spending on health care currently accounts for 18 percent of gross domestic product (GDP), but is anticipated to increase to 25 percent of GDP by 2037. The Bipartisan Policy Center argues that "this rapid growth in health expenditures creates an unsustainable burden on America's economy, with far-reaching consequences". These consequences include crowding out many national priorities, including investments in education, infrastructure, and research; stagnation of employee wages; and decreased international competitiveness.In spite of health care costs that far exceed those of other countries, health outcomes in the United States are not considerably better. With the goal of ensuring that patients have access to high-quality, affordable cancer care, the Institute of Medicine's (IOM's) National Cancer Policy Forum convened a public workshop, Delivering Affordable Cancer Care in the 21st Century, October 8-9, 2012, in Washington, DC. Delivering Affordable Cancer Care in the 21st Century summarizes the workshop.

Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, reviews new, valuable approaches to the treatment of prostate cancer in men. The latest edition contains new material on molecular imaging, new treatments for prostate cancer, molecular targets, cell signaling pathways, bioinformatics, and pathogenomics. The book details the latest innovations and advances in prostate cancer and may be used as a rapid reference text for readers. The volume profiles the latest advances in cancer research and treatment and includes profound studies in prostate stem cells, cancer-host interactions, hedgehog signaling in development and cancer, cholesterol and cell signaling, gene therapy for advanced prostate cancer, and noninvasive strategies such as molecular imaging to visualize gene expression. This new edition also investigates expression profiling and somatic alterations in prostate cancer progression and linkage studies of prostate cancer families to identify susceptibility genes. The issues of racial differences in prostate cancer mortality, radiotherapy for the treatment of locally advanced prostate cancer, recombinant antibody candidates for treatment, taxane-based chemotherapy, lethal phenotypes, and novel and efficient translation clinical trials are also presented in great depth. Prostate Cancer: Biology, Genetics, and the New Therapeutics, Second Edition, provides readers with a general reference for prostate cancer from prevention to therapy and will be of value to clinicians, scientists, and administrators who strive to solve the cancer problem.

Cancer care today often provides state-of-the-science biomedical treatment, but fails to address the psychological and social (psychosocial) problems associated with the illness. This failure can compromise the effectiveness of health care and thereby adversely affect the health of cancer patients. Psychological and social problems created or exacerbated by cancer-including depression and other emotional problems; lack of information or skills needed to manage the illness; lack of transportation or other resources; and disruptions in work, school, and family life-cause additional suffering, weaken adherence to prescribed treatments, and threaten patients' return to health. Today, it is not possible to deliver high-quality cancer care without using existing approaches, tools, and resources to address patients' psychosocial health needs. All patients with cancer and their families should expect and receive cancer care that ensures the provision of appropriate psychosocial health services. Cancer Care for the Whole Patient recommends actions that oncology providers, health policy makers, educators, health insurers, health planners, researchers and research sponsors, and consumer advocates should undertake to ensure that this standard is met.

This thoroughly updated and revised edition of a widely acclaimed book provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. The authors explain the trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. A compact disk accompanies the book for downloading the book to a PC or PDA.

Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists.